Analyst Price Targets — IDXX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 9, 2026 11:54 am | — | Piper Sandler | $750.00 | $644.61 | TheFly | Idexx Laboratories price target lowered to $750 from $775 at Piper Sandler |
| February 5, 2026 10:41 am | Glen Santangelo | Barclays | $800.00 | $642.94 | TheFly | Idexx Laboratories price target lowered to $800 from $850 at Barclays |
| February 3, 2026 12:07 pm | Andrea Alfonso | UBS | $730.00 | $639.60 | TheFly | Idexx Laboratories price target lowered to $730 from $750 at UBS |
| February 3, 2026 2:07 am | — | BTIG | $800.00 | $639.60 | TheFly | Idexx Laboratories price target lowered to $800 from $830 at BTIG |
| December 8, 2025 9:26 pm | Glen Santangelo | Barclays | $850.00 | $706.65 | TheFly | Idexx Laboratories initiated with an Overweight at Barclays |
| November 4, 2025 1:42 pm | — | Morgan Stanley | $805.00 | $721.04 | TheFly | Idexx Laboratories price target raised to $805 from $765 at Morgan Stanley |
| November 4, 2025 12:37 pm | — | UBS | $750.00 | $722.94 | TheFly | Idexx Laboratories price target raised to $750 from $710 at UBS |
| November 4, 2025 12:23 pm | — | BTIG | $830.00 | $722.94 | TheFly | Idexx Laboratories price target raised to $830 from $785 at BTIG |
| November 4, 2025 10:06 am | Keith Devas | Jefferies | $830.00 | $722.94 | StreetInsider | IDEXX Laboratories (IDXX) PT Raised to $830 at Jefferies |
| November 3, 2025 7:45 pm | — | Leerink Partners | $785.00 | $722.94 | TheFly | Idexx Laboratories price target raised to $785 from $745 at Leerink |
Latest News for IDXX
IDEXX Laboratories, Inc. (IDXX) Presents at 47th Annual Raymond James Institutional Investor Conference Prepared Remarks Transcript
IDEXX Laboratories, Inc. (NASDAQ: IDXX - Get Free Report) EVP Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the completion of the sale, the executive vice president owned 19,899
IDEXX Laboratories, Inc. (IDXX) Presents at BofA Securities Animal Health Summit Transcript
Lansforsakringar Fondforvaltning AB publ increased its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 3.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,459 shares of the company's stock after buying an additional 963 shares during the quarter. Lansforsakringar Fondforvaltning AB publ's
IDEXX Laboratories, Inc. (NASDAQ: IDXX - Get Free Report) EVP Michael Erickson sold 5,371 shares of the business's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the transaction, the executive vice president owned 12,693 shares in the company, valued
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.